ACOR News and Press, Acorda Therapeutics Inc. From 07/22/21

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA ® 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU fo...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut...

Midatech Pharma (MTP) +50% on the successful encapsulation of a biologic using Q-Sphera technology.Cellect Biotechnology (APOP) +40%.Clearside Biomedical (CLSD) +23% after filing registration statement for Quoin Pharma merger.Nano-X Imaging (NNOX) +16% after submits 510(k) appl...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021. Prior to their maturity and repayment, there were $69.0 million aggregate principal amount of 2021 notes outstanding. The 2021 notes were repaid...

Whether a #stock moves fast or slow, one thing is always true.  The forces of #supplyanddemand determine the #price of Acorda Therapeutics (NASDAQ: ACOR) and every other stock on the market.  The price someone is willing to pay for ACOR directly impacts its price, but ...

A tell is a precursor of a stock's next move, and #investors in Acorda Therapeutics (NASDAQ: ACOR) look for these #indicators all the time.  the good news is, tells are there for investors to see every day. For example, we have provided this data for ACOR in the trading plans ...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation